New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 7, 2013
09:10 EDTAPPY, APPY, SNTI, SNTI, AEMD, AEMD, INO, INOPR Newswires to host a virtual conference
RetailInvestorConference is being held on February 7 with webcasted company presentations to begin at 9:15 am. Webcast Link
News For APPY;SNTI;AEMD;INO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 29, 2014
07:21 EDTAEMDAethlon Medical discloses ebola treatment pathways in the U.S.
Aethlon Medical will provide Hemopurifier therapy under FDA compassionate use access provisions to support potential requests by qualified physicians and institutes that may seek to treat ebola virus infection in the U.S. The Aethlon Hemopurifier is a first-in-class bio-filtration device that targets the rapid elimination of viruses and immunosuppressive proteins from the circulatory system of infected individuals. Compassionate use provisions are typically approved by FDA on an individual patient basis, but may be expanded to include a small group. Aethlon also plans to submit its first ebola treatment data to the FDA as a means to support the goal of further expanding treatment access through emergency use regulatory pathways. Aethlon is also preparing to initiate U.S. clinical studies of Hemopurifier therapy based on the FDA's approval of an Investigational Device Exemption previously submitted by the company. The study will contribute safety data to advance the device as a broad-spectrum countermeasure against pandemic threats, including ebola and chronic viral pathogens such as HIV and Hepatitis C.
October 27, 2014
18:26 EDTAPPYOn The Fly: After Hours Movers
Subscribe for More Information
16:38 EDTAPPYVenaxis up 3% following presentation of APPY1 trial data
Subscribe for More Information
16:37 EDTAPPYVenaxis presents APPY1 trial results
Venaxis announced the company's pivotal APPY1 Test clinical trial data were presented at the American College of Emergency Physicians Scientific Assembly 2014. The clinical trial involved 29 U.S. hospital sites recruiting patients aged 2 20 from January 2013 through January 2014. Results were presented by Lead Principal Investigator Dr. David S. Huckins, M.D. 1887 patients aged 2 to 20 years with suspected acute appendicitis were included in the study. The results of the study showed the APPY1 Test exhibited a sensitivity of 96.9%, a negative predictive value of 97.3%, a negative likelihood ratio of 0.08, and a specificity of 37.8% for acute appendicitis. Prevalence of disease was 25.3%. The APPY1 Test correctly identified 533 of 1409 patients who did not have appendicitis with 15 false negatives among 478 patients with acute appendicitis. Among patients without appendicitis, 32% who underwent a computed tomography were correctly identified by negative APPY1 Test results. The APPY1 Test is under FDA review and is currently not available for sale in the U.S.
October 21, 2014
06:10 EDTINOInovio, MedImmune, UPENN awarded $12.2M collaborative study by DARPA
Inovio Pharmaceuticals (INO) announced the Defense Advanced Research Projects Agency, or DARPA, has awarded $12.2M for a collaborative study that will be conducted by scientists from the Perelman School of Medicine at the University of Pennsylvania; Inovio Pharmaceuticals; and MedImmune, the global biologics research and development arm of AstraZeneca (AZN). The group will develop DNA-based monoclonal antibodies, or mAbs, for infectious disease treatment. DARPA is an agency of the US Department of Defense that creates and supports novel technologies important for national security. Together, the three organizations will develop and assess the DNA mAbs in preclinical studies using technology developed by Penn and licensed by Inovio. The collaboration will focus on three disease areas influenza virus, Pseudomonas aeruginosa and Staphylococcus aureus.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use